.png)
Staff Profile
Tommy Rennison is a Business Development Manager for the Northern Institute for Cancer Research, a joint position between the Faculty of Medical Sciences Enterprise Team and Cancer Research Technology Limited (the technology transfer arm of the charity Cancer Research UK), which he shares with Phil Elstob.
Roles and Responsibilities
Tommy and Phil are jointly responsible for a strategic alliance between the University and Cancer Research Technology that focuses on the identification, protection, development and commercialisation of novel cancer technologies. Specific activities include:
· Sourcing and evaluating potential new projects (cancer therapies and diagnostics/prognostics)
· Identifying/securing funding for and managing the development of cancer technologies (mainly small molecule drug discovery projects)
· Intellectual property assessment (patentability and freedom to operate), patent filing and prosecution
· Developing and delivering marketing and commercialisation strategies
· Structuring, negotiation and execution of a wide range of intellectual property agreements, and the use of financial models for deal valuation
- Harnor SJ, Rennison T, Galler M, Cano C, Griffin RJ, Newell DR, Golding BT. Synthesis of 3 '-deoxy-3'-fluorothymidine (FLT) 5 '-O-glucuronide: a reference standard for imaging studies with [18F]FLT. MedChemComm 2014, 5(7), 984-988.
- Barrett L, Rennison T, Clapham KM, Rodriguez-Aristegui S, Bardos J, Curtin NJ, Dennis M, Finlay R, Golding BT, Hardcastle IR, Newell DR, Young G, Cano C, Griffin RJ. Development of potent inhibitors of DNA-dependent protein kinase (DNA-PK). In: 245th ACS National Meeting and Exposition. 2013, New Orleans, Louisiana: American Chemical Society.
- Haagensen EJ, Thomas HD, Wilson I, Harnor SJ, Payne SL, Rennison T, Smith KM, Maxwell RJ, Newell DR. The Enhanced In Vivo Activity of the Combination of a MEK and a PI3K Inhibitor Correlates with [18F]-FLT PET in Human Colorectal Cancer Xenograft Tumour-Bearing Mice. PLoS ONE 2013, 8(12), e81763.